Santhera Pharmaceuticals AG Mulls IPO To Finance Drug Development Pipeline

Swiss biotech company Santhera Pharmaceuticals AG is looking at an initial public offering among several other options to finance its drug development pipeline, Chief Executive Klaus Schollmeier said.

MORE ON THIS TOPIC